Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.

@article{Araki2006PharmacogeneticIO,
  title={Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.},
  author={Kazuhiro Araki and Ken-Ichi Fujita and Yuichi Ando and Fumio Nagashima and Wataru Yamamoto and Hisashi Endo and Toshimichi Miya and Keiji Kodama and Masaru Narabayashi and Yasutsuna Sasaki},
  journal={Cancer science},
  year={2006},
  volume={97 11},
  pages={1255-9}
}
Pharmacogenetic testing for UDP-glucuronosyltransferase (UGT) 1A1*28, a promoter variant of the UGT1A1 gene, is now carried out clinically to estimate the risk of irinotecan-associated toxicity. We studied the clinical significance of UGT1A1*6 and UGT1A1*27, two variants in exon 1 of the UGT1A1 gene that are found mainly in Asians. The study group comprised 46 Japanese patients who received various regimens of chemotherapy including irinotecan at doses from 50 to 180 mg/m(2). Pharmacogenetic… CONTINUE READING